Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Switching Between Them

How These Two Drugs Work Differently

Zoledronic acid and romosozumab sit on opposite sides of bone remodeling biology. That difference shapes every decision about sequencing them.

Zoledronic acid (brand name Reclast) belongs to the nitrogen-containing bisphosphonate class. It binds to hydroxyapatite in bone, gets internalized by osteoclasts during resorption, and inhibits farnesyl pyrophosphate synthase inside those cells. The result: osteoclast apoptosis and a sharp drop in bone turnover markers like CTX (C-terminal telopeptide). A single 5 mg IV infusion suppresses resorption for 12 months or longer, which is why annual dosing works 1.

Romosozumab (brand name Evenity) targets sclerostin, a glycoprotein secreted by osteocytes that normally puts the brakes on the Wnt signaling pathway. By neutralizing sclerostin, romosozumab simultaneously stimulates osteoblast-driven bone formation and reduces resorption. This "dual effect" produces rapid BMD gains that peak during the first 6 to 9 months of the 12-month course 2. The formation window is finite: bone turnover markers begin returning toward baseline even before the 12th dose.

That temporary anabolic window is why romosozumab requires a follow-on antiresorptive. Without one, the BMD gained during treatment erodes quickly.

What the Landmark Trials Showed

Each drug's fracture-reduction profile was established in separate large randomized trials. No single study has directly compared zoledronic acid head-to-head with romosozumab.

HORIZON-PFT (N=7,765) randomized postmenopausal women with osteoporosis to zoledronic acid 5 mg IV annually or placebo for three years. At 36 months, the zoledronic acid group had a 70% relative risk reduction in morphometric vertebral fractures (3.3% vs 10.9%), a 41% reduction in hip fractures, and a 25% reduction in nonvertebral fractures 1. Lumbar spine BMD increased by 6.7% over three years versus a 1.3% loss in the placebo arm.

ARCH (N=4,093) compared romosozumab 210 mg SC monthly for 12 months followed by alendronate versus alendronate alone for the full study period. Through 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% compared with alendronate alone (6.2% vs 11.9% cumulative incidence at 24 months). Nonvertebral fracture risk fell by 19%, and clinical fracture risk dropped by 27% 2.

These trials tested different comparators (placebo vs active antiresorptive), different patient populations, and different endpoints. Cross-trial comparisons are inherently limited. The clinical takeaway is not "which drug is better" in isolation but rather how sequencing them together might maximize fracture protection.

Why Sequence Matters More Than Choosing One

The Endocrine Society's 2020 clinical practice guideline on postmenopausal osteoporosis pharmacotherapy recommends considering anabolic therapy first for patients at very high fracture risk, followed by an antiresorptive to consolidate gains 3. The American Association of Clinical Endocrinologists (AACE) 2020 guideline echoes this position, advising that patients with T-scores below -3.0, prior vertebral fractures, or FRAX-calculated 10-year hip fracture probability above 3% should be considered for anabolic-first treatment 4.

The rationale is pharmacologic, not just clinical. Antiresorptive drugs fill the remodeling space (the volume of bone currently being resorbed and rebuilt). Starting a bisphosphonate first fills that space with undermineralized bone. If you then switch to an anabolic agent, the osteoblasts have less surface area to work with. The "anabolic blunting" phenomenon was demonstrated clearly in the DATA study of teriparatide and denosumab: patients who received denosumab first and then switched to teriparatide actually lost hip BMD during the first year of the anabolic 5.

Romosozumab appears somewhat less susceptible to this blunting than teriparatide, but the principle holds. The largest BMD response occurs when the anabolic is given to treatment-naive bone.

Switching from Evenity to Reclast: The Preferred Direction

Starting romosozumab for 12 months and following with zoledronic acid is the sequence most consistent with guideline recommendations. This is the direction supported by the strongest indirect evidence.

In the ARCH trial, patients who received 12 months of romosozumab followed by alendronate continued to accrue BMD at the lumbar spine and total hip during the antiresorptive phase 2. The fracture protection observed at 24 months reflected both the initial anabolic window and the sustained benefit of the follow-on bisphosphonate.

While ARCH used oral alendronate as the follow-on agent, IV zoledronic acid is a reasonable (and often more practical) alternative. A single annual infusion eliminates concerns about oral bisphosphonate adherence, esophageal irritation, and fasting requirements. The Endocrine Society guideline does not specify which bisphosphonate to use as follow-on therapy, and the choice between alendronate, risedronate, and zoledronic acid is typically guided by patient preference and tolerability 3.

Timing matters. The transition from romosozumab to zoledronic acid should happen within one month of the final romosozumab dose. Delaying the follow-on antiresorptive by even a few months allows bone turnover to rebound. Data from denosumab discontinuation studies show that rebound resorption can erase years of BMD gains within 12 to 24 months 6. Romosozumab's offset is likely faster than denosumab's given its shorter half-life (approximately 12.8 days vs denosumab's approximately 25.4 days).

Practical protocol: administer the last romosozumab injection at month 12, then schedule the first zoledronic acid infusion at month 13. Continue zoledronic acid annually for 3 to 6 years depending on fracture risk reassessment.

Switching from Reclast to Evenity: When It Makes Sense

Switching from zoledronic acid to romosozumab is less commonly discussed in guidelines but is clinically relevant for patients who remain at very high fracture risk despite bisphosphonate therapy.

The scenario: a patient has received 3 to 6 years of zoledronic acid, has a recent vertebral fracture or persistent T-score below -2.5, and needs escalation. Can romosozumab still work after years of antiresorptive suppression?

Evidence from the STRUCTURE trial (which studied teriparatide vs romosozumab in patients transitioning from bisphosphonates) provides some insight. In STRUCTURE (N=436), postmenopausal women who had received at least 3 years of oral bisphosphonates were randomized to romosozumab or teriparatide for 12 months. Romosozumab increased total hip BMD by 2.6% versus 0.5% loss with teriparatide at 12 months 7. Lumbar spine BMD rose 9.8% with romosozumab versus 5.4% with teriparatide in this bisphosphonate-pretreated population.

So romosozumab does still work after bisphosphonate exposure. The BMD gains are real and clinically meaningful. But they are smaller than what treatment-naive patients experience. The anabolic window is partially narrowed, consistent with the pharmacologic principle described above.

One practical concern with this switch direction: the bisphosphonate skeleton retains drug for years after the last dose. Zoledronic acid's terminal elimination half-life exceeds 10 years because of skeletal binding. This residual antiresorptive effect may dampen the full remodeling response to romosozumab, though the STRUCTURE data suggest the dampening is modest at worst 7.

After completing 12 months of romosozumab in this scenario, the patient should transition back to an antiresorptive. Zoledronic acid is again a logical choice, creating a bisphosphonate-to-anabolic-to-bisphosphonate "sandwich" sequence.

Head-to-Head Efficacy: What We Can and Cannot Say

No randomized controlled trial has directly compared zoledronic acid with romosozumab using the same comparator, endpoints, and population. Any ranking of "better versus worse" is speculative.

What the data allow us to say:

Romosozumab produces faster and larger BMD increases at the lumbar spine over 12 months than any bisphosphonate achieves in the same timeframe. In FRAME (N=7,180), romosozumab increased lumbar spine BMD by 13.3% at 12 months versus 0.0% with placebo 8. Zoledronic acid in HORIZON-PFT increased lumbar spine BMD by approximately 4.3% at 12 months versus placebo 1.

For hip fracture reduction, zoledronic acid has a 41% relative risk reduction versus placebo in HORIZON-PFT. Romosozumab's hip fracture data are less definitive: ARCH showed a 38% reduction versus alendronate, but the comparison was against an active drug, not placebo, making absolute effect estimates difficult to compare 2.

The AACE guideline panel characterized romosozumab as "very high fracture risk" therapy and zoledronic acid as appropriate for "high fracture risk" (T-score between -2.5 and -3.0 without prior fracture) or as follow-on therapy after an anabolic 4.

Safety Profiles Shape the Sequencing Decision

Zoledronic acid's safety profile is well characterized over nearly two decades of clinical use. The most common adverse event is an acute-phase reaction (fever, myalgia, headache) occurring in 30 to 35% of patients after the first infusion and declining sharply with subsequent doses. Rare risks include osteonecrosis of the jaw (ONJ), estimated at 1 per 10,000 to 1 per 100,000 patient-years in the osteoporosis population, and atypical femoral fractures (AFF), with incidence rising after 5 or more years of bisphosphonate use 9. Renal function must be checked before each infusion; zoledronic acid is contraindicated when creatinine clearance falls below 35 mL/min.

Romosozumab carries a boxed warning for cardiovascular risk. In ARCH, major adverse cardiovascular events (MACE) occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over the initial 12-month period 2. The FDA label states romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. The FRAME trial, which used a placebo comparator, did not show the same cardiovascular signal (0.6% romosozumab vs 0.6% placebo) 8. Whether this represents a true drug effect or a population-level confound remains debated.

Injection-site reactions occur in approximately 5% of romosozumab patients. Hypocalcemia is possible with either drug and requires adequate calcium and vitamin D supplementation throughout treatment.

The cardiovascular warning effectively rules out romosozumab for a subset of the osteoporosis population. For those patients, zoledronic acid (or denosumab) becomes the primary option regardless of fracture risk tier.

Cost and Access Considerations

The price gap between these two therapies is substantial and influences real-world sequencing decisions.

Generic IV zoledronic acid costs approximately $300 to $500 per annual infusion at most infusion centers, though facility fees can raise the total to $1,000 to $2,000 depending on the setting. Medicare Part B covers IV zoledronic acid as a medical benefit, which often results in lower out-of-pocket costs than oral bisphosphonates under Part D 10.

Romosozumab carries a wholesale acquisition cost of approximately $1,800 per monthly injection, totaling roughly $21,600 for the full 12-month course. Most commercial insurers and Medicare Part D plans require prior authorization, step therapy through a bisphosphonate, or both. Some patients face tier 4 or 5 copays exceeding $200 per month even with coverage. Amgen's patient assistance program (Evenity Together) may reduce costs for eligible patients, but access remains a barrier for many.

For patients with very high fracture risk who can access romosozumab, the anabolic-first strategy followed by generic zoledronic acid may be cost-effective over a 5-year horizon because of the larger fracture reduction and the low ongoing cost of annual IV zoledronic acid. For patients who cannot access romosozumab due to cost, cardiovascular contraindications, or insurance denials, zoledronic acid alone remains a highly effective first-line option with decades of fracture-reduction data behind it.

Building a Treatment Sequence: Decision Framework

The optimal sequence depends on three variables: fracture risk tier, cardiovascular history, and access.

For very high fracture risk patients (prior vertebral fracture, T-score <-3.0, high FRAX) with no recent cardiovascular event and insurance coverage for romosozumab: start romosozumab 210 mg SC monthly for 12 doses, then transition to zoledronic acid 5 mg IV annually. Reassess after 3 years of zoledronic acid with DXA and vertebral fracture assessment.

For very high fracture risk patients with recent MI/stroke or romosozumab access barriers: start zoledronic acid 5 mg IV annually. If fracture risk remains very high after 3 to 6 years (persistent low T-score, incident fracture on therapy), consider a bisphosphonate holiday followed by romosozumab if cardiovascular risk has resolved and access permits.

For high fracture risk patients (T-score -2.5 to -3.0, no prior fracture): zoledronic acid is appropriate as initial therapy. The incremental benefit of anabolic-first sequencing is smaller in this risk tier, and the cost-benefit ratio shifts toward starting with a bisphosphonate 4.

Dr. Felicia Cosman, professor of medicine at Columbia University and lead author of the National Osteoporosis Foundation's Clinician's Guide, has stated: "The treat-to-target concept in osteoporosis means selecting initial therapy intensity based on fracture risk, not defaulting to the least potent option first" 3.

The AACE 2020 guideline authors wrote: "For patients at very high risk, initial treatment with bone-forming therapy for up to 12 months for romosozumab followed by anti-resorptive therapy is recommended" 4.

Monitoring During and After the Switch

Bone turnover markers (BTMs) can help confirm that sequencing is working as intended. Procollagen type I N-terminal propeptide (P1NP), a formation marker, rises sharply within the first month of romosozumab and peaks around month 3 to 6. CTX, the resorption marker, drops simultaneously during romosozumab treatment. After transitioning to zoledronic acid, P1NP falls (the anabolic stimulus is gone) and CTX remains suppressed (the bisphosphonate is now doing the antiresorptive work) 7.

DXA should be repeated at 12 months after starting romosozumab (before transitioning) and again 12 months after starting zoledronic acid. A lumbar spine BMD gain of 5% or more during the romosozumab phase and maintenance or continued modest gain during the zoledronic acid phase indicates the sequence is performing as expected.

If BMD declines on zoledronic acid after romosozumab, confirm medication adherence (infusion records), check vitamin D levels (target 25-hydroxyvitamin D above 30 ng/mL), and rule out secondary causes of bone loss such as glucocorticoid use, hyperparathyroidism, or celiac disease.